March 2021 Review of news from the most innovative therapeutic areas and the business development transactions.

After the constant long-term growth of Nasdaq Biotech Index, a significant drop was seen in February and March. The index lost 14 % compared to its February peak, which is the worst drop in a year. Rising interest rates and investors’ refocus on 2020 down-beaten industries could be a reason.